Updated:
Veraxa Biotech said Wednesday, October 7, that it is applying FDA-aligned New Approach Methodologies across its preclinical research programs, using human-relevant laboratory and computational approaches intended to reduce reliance on animal testing. The announcement included company-reported results from an ex vivo study of cancer-drug candidates; Veraxa said the work used about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies.
Shares of the Nasdaq-listed company, ticker VRXA, were reported at $1.14 in premarket trading, up 5.79%, after closing Tuesday at $1.08, down 4.42%. The premarket move followed the research update, though the available reporting does not establish that the announcement alone caused the share-price change.
Models span laboratory and computational methods
Veraxa’s described toolkit includes cell-based assays, three-dimensional tumor spheroid models, computational modeling and ex vivo tissue models. These methods are intended to help assess how candidate therapies interact with human-relevant biological systems while reducing dependence on conventional animal studies.
The company said it is applying the approaches across its programs, including BiTAC-based T-cell engagers, BiTAC antibody-drug conjugates and bispecific antibody-drug conjugates. The announcement did not disclose a development timetable, independent validation of the company’s results, or a specific regulatory decision accepting these methods for a future application.
Company reports results from lung-cancer model panel
Veraxa said it evaluated lead BiTAC-TCE and bispecific ADC candidates in an ex vivo panel of 10 low-passage, patient-derived xenograft models of non-small cell lung cancer. According to the company’s account, the panel required approximately 10 mice in total; it compared that figure with an estimate of at least 200 mice for similar in vivo efficacy studies.
The company reported that its combined BiTAC approach induced T-cell-mediated killing across the panel, while commercial T-cell engagers directed at targets not expressed in the models showed minimal activity. Those findings are company-reported preclinical results, not evidence of effectiveness or safety in patients. Veraxa also said its spheroid studies showed T-cell engagement specificity across cancer cell lines, supporting further use of the model in studies intended to prepare for an investigational new drug application.
FDA policy encourages alternatives but does not guarantee acceptance
The strategy follows an FDA effort, announced in April 2025, to reduce animal testing in preclinical safety studies and encourage scientifically supported alternatives. The agency’s roadmap identifies approaches such as computational modeling, advanced in vitro tests and human-derived platforms. In March 2026, FDA also issued draft guidance on considerations for validating new approach methodologies in drug development.
That policy direction gives Veraxa’s announcement a regulatory context, but it does not mean that a particular model or dataset has been cleared for use in a specific drug submission. FDA guidance emphasizes method validation and recommends that developers consult the relevant review division when considering new methodologies. Whether Veraxa’s models can support individual regulatory decisions will depend on the methods, evidence and proposed use.
Clinical and regulatory milestones remain unspecified
Veraxa develops antibody-based cancer therapies, including conditionally active T-cell engagers and antibody-drug conjugates. The company previously presented initial data on its BiTAC-TCE program at the 2026 annual meeting of the American Association for Cancer Research, according to same-day reporting.
The October 7 announcement did not specify which studies would come next, when any candidate might enter clinical testing, or whether the company expects to omit particular animal studies for a named program. The preclinical findings and proposed efficiencies therefore remain early-stage company disclosures, rather than confirmed clinical or regulatory outcomes.
